Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Ch... (safetyprofile and promising clinical out...)

HOME >> MEDICINE >> TECHNOLOGY

Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Date:10/26/2008

safety profile and promising clinical outcomes comparable to other antibiotics either on the market or in development. What is most encouraging about PTK 0796 is that it is the first broad-spectrum antibiotic with activity against MRSA that will have the oral and IV formulations needed for seamless transition of treatment from the hospital out into the community. I look forward to continued progress of this program."

PTK 0796 represents a new class of antibiotics that has shown potent, broad-spectrum activity against multi-drug resistant and susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), as well as Gram-negative, anaerobic and atypical bacteria. Paratek is developing PTK 0796 as a firstline agent for empiric therapy for the leading infections requiring hospitalization, such as cSSSIs and moderate to severe community-acquired pneumonia (CAP).

Thomas J. Bigger, Paratek's President and CEO, stated, "PTK 0796 is the only once-a-day, oral and IV MRSA-active compound in development with a spectrum broad enough for single agent treatment of cSSSI and CAP. These attributes have generated great enthusiasm and interest among investigators planning to participate in our Phase 3 program. We expect to initiate our pivotal Phase 3 trials in the U.S. and overseas for the treatment of cSSSI patients, including those with diabetic foot infections, in the first quarter of 2009. We are thrilled by the rapid advancement of these efforts and by the ability to present our Phase 2 results at the leading infectious diseases conference."

Background on Aminomethylcyclines (AMCs)

Using Paratek's novel medicinal chemistry techniques, AMCs were evolved from tetracycline antibiotics as potential agents to combat multiple antibiotic-resistant bacteria, including MRSA, penicillin-resistant Streptococcus pneumoniae (PRSP), vancomycin-resistant Enterococcus (VRE), multidrug resistant Escherichia coli and other difficult-t
'/>"/>

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
2. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
3. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women

Post Your Comments:

Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Ch...(safetyprofile and promising clinical out...),Health